62 results about "Cannabielsoin" patented technology

A method for the administration of nicotine, THC, tobacco, cannabidiol or a base alkaloid includes administering in the oral or nasal cavity an absorption conditioning unit having at least two agents selected from the group consisting of (a) a buffer agent, (b) a capturing agent, (c) a penetration agent, and (d) a thermal agent, to the mammal, and then administering by inhalation a bioactive agent selected from the group consisting of nicotine, THC, cannabidiol and a base alkaloid. The absorption conditioning unit may be in a dosage form not containing a drug. The absorption conditioning unit may create a pH in the oral cavity or nasal cavity of 7.8-10 for a period of ten minutes or more after administration, the dosage form not containing an acid and not containing a drug.

A method for the administration of nicotine, THC, tobacco, cannabidiol or a base alkaloid includes administering an absorption conditioning unit having at least two agents selected from the group consisting of (a) a buffer agent, (b) a capturing agent, (c) a penetration agent, and (d) a thermal agent, to the mammal, and then administering by inhalation a bioactive agent selected from the group consisting of nicotine, THC, cannabidiol and a base alkaloid. The absorption conditioning unit may be in a dosage form not containing a drug. The absorption conditioning unit may create a pH in the oral cavity of 7.8-10 for a period of ten minutes or more after administration, the dosage form not containing an acid and not containing a drug.

A disposable cartridge is disclosed for use with an electronic device for producing an aerosol for inhalation by a person. The cartridge comprises a liquid container containing a liquid which when aerosolized is intended for inhalation by a person; and a transducer that, when actuated, causes the liquid from the container to be aerosolized such that the aerosol may be inhaled by a person. In various embodiments, the liquid comprises: a liposomal carrier; a liquid mixture having an active agent entrapped by liposomes; and a liquid mixture comprising a nanodispersion. The liquid may include nicotine, tetrahydrocannabinol, cannabidiol, or nanoparticles formed by an oil droplet covered by a monolayer of phosphatidylcholine. The transducer preferably comprises a mesh material with the transducer and the mesh material forming a piezo mesh disk for aerosolizing the liquid.

The invention discloses a method for extracting and separating high-purity cannabidiol (CBD) from low-content industrial hemp floral leaves. The method adopts the modes of digestion, macroporous resinadsorption and desorption, reverse chromatography and crystallization to finally obtain a cannabidiol pure product with the purity of 99% or above. In order to separate other cannabinoids, extractionand decoloration processes can be added between the digestion process and the macroporous resin adsorption and desorption process, and a polymer reversed-phase filler is used for reversed-phase chromatography, so that cannabidivarin (CBDV), cannabinol (CBN) and tetrahydrocannabinol (THC) in the floral leaves can be separated. The method disclosed by the invention is high in digestion, extractionand decoloration process yield and high in impurity removal rate; the macroporous resin and reversed-phase column chromatography have the advantages of high loading capacity and favorable separation effect. Requirements of development of a plurality of industrial hemp products are met, and the method has great application advantages in the pharmaceutical field and is suitable for industrial popularization.

The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). In particular the CBD was able to decrease the number and size of marker cells, pS6, in a zebrafish model of TSC. This is5 suggestive of a disease modifying effect whereby treatment with CBD could result in the reduction or prevention of the benign tumours that occur in TSC patients. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially 10 removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD. In use the CBD is given concomitantly with one or more other drugs used in the treatment of TSC. Such drugs may include rapamycin and/or everolimus.

The invention relates to the technical field of detection, in particular to a qualitative and quantitative detection method of one or more of cannabidiol, cannabidiolic acid and tetrahydrocannabinol.The qualitative and quantitative detection method of one or more of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol comprises the following steps that: ultrasound extraction is conducted on smashed hemp flower leaves through methyl alcohol, and a test solution is obtained; the test solution is separated and detected through high performance liquid chromatography, a moving phase of the high performance liquid chromatography is a mixture of acetic acid water solution and acetonitrile, and isocratic elution is conducted; and the content of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol are detected through an external standard method. According to the qualitative and quantitative detection method of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol, specific wave length and a moving phase are selected, the peak pattern is good, sensitivity is high, research is conveniently conducted, and qualitative and quantitative treatment of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol can be detected quickly and accurately under treatment of the same sample.

Compositions comprising two or more cannabinoids, a terpene, and a flavonoid suitable for use in treating insomnia are disclosed. In preferred embodiments, the cannabinoids are cannabidiol and tetrahydrocannabinol, while the terpenes and flavonoids are selected from compounds that naturally occur in Cannabis extracts. Methods of treating insomnia by administering such compositions by a variety of routes are also disclosed.

Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.

Mutations in keratin genes or the genes that regulate keratin expression can result in epithelial cells lacking sufficient structural integrity. The resulting disruption of connective tissue gives rise to inherited disorders such epidermolysis bullosa. It has been found that various cannabinoids (including mixtures of cannabidiols and cannabinol) upregulate expression of various keratins such that loss of function in other keratin genes may be compensated for. By way of this upregulation, these cannabinoids can be used to treat epidermolysis bullosa and other connective tissue disorders arising from intermediate filament dysfunction.

The invention discloses an aerosol comprising industrial hemp floral leaf essential oil and medicinal components. The industrial hemp floral leaf essential oil added in the invention only contains micromolecular aromatic components and does not contain diterpenoid compounds such as cannabidiol, tetrahydrocannabinol and other medicinal active components, so that the biological activity of an addedobject is not obviously influenced. However, after the industrial hemp floral leaf essential oil is added, all odorless cannabinol products have the symbolic aroma of natural industrial hemp, the sensory deficiency, psychological comfort and implication effects are supplemented, and the market value of the original products and the cognition degree of consumers can be greatly improved. The industrial hemp floral leaf essential oil is added into the odorless cannabinol aerosol, so that the acceptability of patients using natural medical hemp to odorless products can be improved.

The present invention discloses a cytotoxic cocktail comprising; (a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, and any combination thereof; and (b) at least one therapeutic agent selected from the group consisting of: bortezomib (BTZ), carflizomib (CFZ), lenalidomide (LEN), dexamethasone (DEX), melphalan (MEL) and doxorubicin (DOXO). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (MM) cells, relative to said at least one therapeutic agent selected from the group consisting of: BTZ, CFZ, LEN, DEX, MEL, DOXO and said CBD and THC, administered separately in a similar concentration.

A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include Δ⁹-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including Δ⁹-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable Δ8-tetrahydrocannabinol. The known and novel analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis or cannabis oil.

The invention belongs to the field of analytical chemistry, and particularly relates to a method for simultaneously detecting five cannabinol compounds by using a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). According to the method, a special chromatographic column for cannabinol is adopted, a formic acid aqueous solution is used as a mobile phase A, acetonitrile is used as a mobile phase B for gradient elution, and a sample enters a detector for detection. The cannabinol compound is tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinol (CBN), cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC). The method is high in detection sensitivity, good in recovery rate and easy to operate.

The invention relates to a chromatographic separation method of a cannabinoid compound, which comprises chromatographic separation on cannabis sativa extract by adopting an ethanol aqueous solution, and comprises the following steps: (1) washing for impurity removal: washing impurities by adopting a 50-70 (volume)% ethanol aqueous solution of 2BV, (2) gradient elution: adopting 75%-95% (volume) ofan ethanol aqueous solution as a gradient elution solvent, and respectively collecting an eluent of the first BV to the second BV, an eluent of the 2.5th to the fourth BV and an eluent of the fourthBV to the sixth BV, and (3) concentration: respectively concentrating the eluents collected in the step (2). By adopting the method disclosed by the invention, the high-purity hypocannabidiol, cannabidiol and tetrahydrocannabinol can be directly separated, and the purity of the hypocannabidiol, cannabidiol and tetrahydrocannabinol reaches up to 95% or above after the eluent is concentrated.

Systems, apparatus, and methods for transacting, recording, validating and/or verifying agricultural products. The 2018 Farm Act rescinded industrial hemp from Schedule I of the Controlled Substances Act (CSA). Although industrial hemp has a variety of uses ranging from concrete, insulation, paper products, and rope; the Government's biggest concern is the ingestion of tetrahydrocannabinol (THC) and cannabidiol (CBD). Commercial regulation typically balances a variety of factors: e.g., consumer protection, regulatory overhead, market competition, tax revenue, public policy, etc. In contrast, law enforcement has a singular purpose, and may go to extraordinary lengths to stop criminal activity. Various embodiments described herein provide a blockchain ledger-based supply chain that allows many commercial and regulatory entities to independently cooperate. Every transaction is permanently and transparently recorded within a chain-of-custody; the chain-of-custody enables a traceability. A variety of new applications are enabled by the blockchain ledger-based supply chain.

The invention provides compositions and methods for the breeding, production, processing and use of Specialty Cannabis and oannabinoid compositions. The Specialty Cannabis plants, plant parts, plant tissues and plant cells of the present disclosure comprise high levels of CBG in combination with one or more other cannabinoids.

The invention relates to a method for separating and purifying cannabinol from industrial hemp, and belongs to the technical field of chemistry. The method includes following steps: adding an ethanolsolution into the cannabinol crude product and stirring the solution to obtain a crude product ethanol solution; uniformly adding the crude ethanol solution into the activated macroporous resin column; carrying out normal-pressure elution on the macroporous resin by using a first ethanol solution to obtain a first eluent and first-time eluted macroporous resin; and performing normal-pressure elution on the macroporous resin subjected to primary elution by using a second ethanol solution to obtain a second eluent, adding a third ethanol solution into the second concentrated solution to obtain aconcentrated ethanol solution, and filtering and drying crystals to obtain cannabinol, of which the content is greater than or equal to 95%. The method has the beneficial effects that the high-puritycannabinol is obtained by separating the cannabinol according to the huge difference between the peak appearance time of the cannabinol in the reversed-phase column and other cannabinoid substances and then crystallizing the cannabinol; the method is simple to operate, low in cost and suitable for industrial production, and the problem of separation and purification of the cannabinol is solved.